JOHN BILLON: Open Payments
NPI 1083714653 · ARNOLD, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,038 in 92 payments from 25 companies in 2025. Trend: 2023 $1,711 · 2024 $1,449 · 2025 $2,038
Food & beverage: $2,038
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 22 | $505 |
| ABBVIE INC. | 12 | $268 |
| Lilly USA, LLC | 14 | $240 |
| Astellas Pharma US Inc | 5 | $136 |
| Madrigal Pharmaceuticals | 1 | $108 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $105 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $86 |
| PFIZER INC. | 3 | $67 |
| Exact Sciences Corporation | 3 | $65 |
| AstraZeneca Pharmaceuticals LP | 3 | $59 |
Products named: Rybelsus, Wegovy, VRAYLAR, MOUNJARO, Ozempic, Veozah, REZDIFFRA, XIFAXAN.
Industry payments across MD — which companies pay providers there.
